MPM Capital
MPM Capital is a healthcare investment firm that focuses on the biotechnology, healthcare, and life sciences sectors. Established in 1996 and headquartered in Boston, Massachusetts, with additional offices in California and Kansas, the firm specializes in investing in companies that develop therapeutic technologies, particularly in oncology and medical technology. MPM Capital targets a range of investment stages, from seed and early ventures to late-stage biopharmaceutical and diagnostics companies with clinical proof-of-concept. The firm typically invests between $5 million and $50 million and seeks to be a lead investor, often taking interim operating roles within its portfolio companies. Its global investment strategy emphasizes opportunities in the United States, Europe, and Asia, particularly India, with a commitment to translating scientific innovations into clinical outcomes that can significantly impact patient lives.
Aratana Therapeutics
Series C in 2013
Aratana Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for dogs and cats in the United States. Founded in 2010 and based in Leawood, Kansas, the company offers a range of products including NOCITA for post-operative pain management in dogs, ENTYCE for appetite stimulation, and GALLIPRANT for osteoarthritis pain and inflammation. Additionally, it is advancing several therapeutic candidates, such as a bupivacaine liposome injectable suspension for cats, a formulation of capromorelin for appetite stimulation in cats, and treatments for atopic dermatitis and feline herpes virus. Aratana collaborates with other organizations, including Elanco Animal Health and Pacira Pharmaceuticals, to enhance its product development and commercialization efforts. The company aims to address unmet needs in companion animal healthcare by leveraging proprietary technologies and scientific advancements.
Aratana Therapeutics
Series B in 2011
Aratana Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for dogs and cats in the United States. Founded in 2010 and based in Leawood, Kansas, the company offers a range of products including NOCITA for post-operative pain management in dogs, ENTYCE for appetite stimulation, and GALLIPRANT for osteoarthritis pain and inflammation. Additionally, it is advancing several therapeutic candidates, such as a bupivacaine liposome injectable suspension for cats, a formulation of capromorelin for appetite stimulation in cats, and treatments for atopic dermatitis and feline herpes virus. Aratana collaborates with other organizations, including Elanco Animal Health and Pacira Pharmaceuticals, to enhance its product development and commercialization efforts. The company aims to address unmet needs in companion animal healthcare by leveraging proprietary technologies and scientific advancements.
Aratana Therapeutics
Series A in 2011
Aratana Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for dogs and cats in the United States. Founded in 2010 and based in Leawood, Kansas, the company offers a range of products including NOCITA for post-operative pain management in dogs, ENTYCE for appetite stimulation, and GALLIPRANT for osteoarthritis pain and inflammation. Additionally, it is advancing several therapeutic candidates, such as a bupivacaine liposome injectable suspension for cats, a formulation of capromorelin for appetite stimulation in cats, and treatments for atopic dermatitis and feline herpes virus. Aratana collaborates with other organizations, including Elanco Animal Health and Pacira Pharmaceuticals, to enhance its product development and commercialization efforts. The company aims to address unmet needs in companion animal healthcare by leveraging proprietary technologies and scientific advancements.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.